curasafehealthcare.com
  • Home
  • About
  • Services
  • Therapeutic Areas
  • Careers
  • Latest News
  • Contact Us
Select Page

Sonidegib in Adult Patients with Locally Advanced Basal Cell Carcinoma (laBCC) in China

by palligoelme@gmail.com | Mar 18, 2025 | Clinical Trials

​ Conditions: Carcinoma, Basal Cell (BCC) Interventions: Drug: Sonidegib Phosphate Capsules Sponsors: Jemincare; Sun Pharmaceutical Industries Limited; Zhejiang Hangyu Pharmaceutical Co., Ltd. Active, not recruiting Conditions: Carcinoma, Basal Cell (BCC)...

SPINEPASS: SPINE Self-management Techniques for Persistent Headache After Concussion: Physical Therapy Targeting Autonomic and Dura Mater Function.

by palligoelme@gmail.com | Mar 18, 2025 | Clinical Trials

​ Conditions: Persistent Post-concussive Symptoms; Post Traumatic Headache Interventions: Other: SPINEPASS Physical Therapy; Other: Standard Physical Therapy Sponsors: The University of Queensland; Brooke Army Medical Center; United States Department of Defense Not...

Development in Children Diagnosed with Congenital Muscular Torticollis

by palligoelme@gmail.com | Mar 18, 2025 | Clinical Trials

​ Conditions: Torticollis Congenital; Motor Development; Sensory Integration Dysfunction Sponsors: Gazi University Recruiting Conditions: Torticollis Congenital; Motor Development; Sensory Integration Dysfunction Sponsors: Gazi University...
Gene therapy for blood cancer shows 73 per cent response rate in clinical trials: Lancet study

Gene therapy for blood cancer shows 73 per cent response rate in clinical trials: Lancet study

by palligoelme@gmail.com | Mar 18, 2025 | Clinical Trials

​  A new study published in The Lancet Haematology journal says that an indigenously developed gene therapy for certain blood cancers has shown a 73 per cent response rate among patients in India. Read on to know more.  A new study published in The Lancet Haematology...
Pan-kinase inhibitor for head and neck cancer enters clinical trials

Pan-kinase inhibitor for head and neck cancer enters clinical trials

by palligoelme@gmail.com | Mar 18, 2025 | Clinical Trials

​  A drug targeting the scaffolding function of multiple related kinases halts tumor progression.  A drug targeting the scaffolding function of multiple related kinases halts tumor progression. 
« Older Entries
Next Entries »

Recent Posts

  • The Efficacy of a Polarized Folded Optical Path-based Reading-writing Desk for Myopia Prevention and Control in Pre-myopic Children
  • MUTTON-HF Pilot Expansion
  • Sleep Quality Among Dentists
  • Video-based Visual Feedback Combined With Task-oriented Physiotherapy Among Cerebral Palsy
  • Dietary Supplementation and Hydration

Recent Comments

No comments to show.

Curasafe healthcare solutions Pvt. Ltd. provides comprehensive services including safety program oversight, risk management, and regulatory compliance.

Important Links

  • Home
  • Contact Us
Connect With Us

Contact


711, Shivalik Satyamev, Bopal Ambli Junction, Bopal, Ahmedabad, Daskroi, Gujarat, India, 380058.


info@curasafehealthcare.com



(+91) 97803 81065

Copyright © 2025 Curasafehealthcare ®